Pfizer and Big Pharma “Desperate” for Bio Acquisitions: 2007 M&A Predictions from Jeff Kraws of Crystal Research Associates

Large cap big pharma companies have been called "dinosaurs," when compared to small and agile biotech companies, and clearly they're losing patents faster than they can add new products.  Analyst Jeff Kraws expects to see large companies, particularly Pfizer, snap up nimble biotechs to close their innovation gaps.  A Pfizer acquistion is likely this year, he suggests.

Play Video

Pharma M&A Outlook - Part 2 - Bloomberg

Bloomberg - (BLOOM)

Feb. 22, 2007. 07:45 AM EST

Large cap pharma companies are likely to invest in late stage oncology or anti-infective biotechs, says Crystal Research Associates analyst Jeff Kraws in the conclusion of his interview today.

Play Video

Pharma M&A Outlook - Part 2 - Bloomberg

Bloomberg - (BLOOM)

Feb. 22, 2007. 07:45 AM EST

Large cap pharma companies are likely to invest in late stage oncology or anti-infective biotechs, says Crystal Research Associates analyst Jeff Kraws in the conclusion of his interview today.